Literature DB >> 9675258

Activation and detoxication of aflatoxin B1.

F P Guengerich1, W W Johnson, T Shimada, Y F Ueng, H Yamazaki, S Langouët.   

Abstract

Aflatoxin B1 (AFB1) is a potent hepatocarcinogen in experimental animals and a hazard to human health in several parts of the world. Implementation of rational intervention plans requires understanding of aspects of the roles of individual chemical steps involved in its disposition. AFB1 is activated to AFB1 exo-8,9-epoxide primarily by cytochrome P450 (P450) enzymes, particularly P450 3A4. However, P450 3A4 and other P450s also oxidize AFB1 to less dangerous products. The exo-epoxide is unstable in H2O (t1/2 1 s at 25 degreesC, k=0.6 s-1) and the diol product undergoes base-catalyzed rearrangement to a dialdehyde that reacts with protein lysine residues. AFB1 exo-8, 9-epoxide reacts with DNA to give adducts in high yield (>98%). This interaction is characterized by a Kd of approximately 1.4 mM, intercalation between base pairs, and rapid reaction with the guanyl N7 atom (k approximately 40 s-1). A proton field on the periphery of DNA is postulated to catalyze hydrolysis and also conjugation. Rat and especially human epoxide hydrolase show very little rate acceleration of hydrolysis of AFB1 exo- or endo-8,9-epoxide. However, glutathione transferases (GSTs) can catalyze AFB1 exo-8,9-epoxide conjugation. Kinetic analysis indicates a range of ratios of kcat/Kd varying from 10 to 1700 s-1 M-1, with the polymorphic GST M1-1 having the highest activity of the human GSTs. Studies with human hepatocytes indicate a major role for GST M1-1 in AFB1 conjugation and that the model chemoprotective agent oltipraz can act by both inducing GSTs and inhibiting P450s. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675258     DOI: 10.1016/s0027-5107(97)00289-3

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  50 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma.

Authors:  Yu-Jing Zhang
Journal:  World J Hepatol       Date:  2010-03-27

3.  cis-Terpenones as an effective chemopreventive agent against aflatoxin B1-induced cytotoxicity and TCDD-induced P450 1A/B activity in HepG2 cells.

Authors:  Qibing Zhou; Hang Xie; Lin Zhang; Jennifer K Stewart; Xing-Xing Gu; John J Ryan
Journal:  Chem Res Toxicol       Date:  2006-11       Impact factor: 3.739

4.  Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression.

Authors:  Kerstin Gross-Steinmeyer; Patricia L Stapleton; Julia H Tracy; Theo K Bammler; Stephen C Strom; David L Eaton
Journal:  Toxicol Sci       Date:  2010-05-04       Impact factor: 4.849

5.  XPC codon 939 polymorphism is associated with susceptibility to DNA damage induced by aflatoxin B1 exposure.

Authors:  Xi-Dai Long; Hong-Dong Huang; Xiao-Ying Huang; Jin-Guang Yao; Qiang Xia
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  Toxicity of aflatoxin B1 to Helicoverpa zea and bioactivation by cytochrome P450 monooxygenases.

Authors:  Ren Sen Zeng; Ren Sen L Zeng; Guodong Niu; Zhimou Wen; Mary A Schuler; May R Berenbaum
Journal:  J Chem Ecol       Date:  2006-06-01       Impact factor: 2.626

Review 7.  Mode of action-based risk assessment of genotoxic carcinogens.

Authors:  Andrea Hartwig; Michael Arand; Bernd Epe; Sabine Guth; Gunnar Jahnke; Alfonso Lampen; Hans-Jörg Martus; Bernhard Monien; Ivonne M C M Rietjens; Simone Schmitz-Spanke; Gerlinde Schriever-Schwemmer; Pablo Steinberg; Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-15       Impact factor: 5.153

8.  CYP1A1 I462V polymorphism is associated with reduced genotoxicity in yeast despite positive association with increased cancer risk.

Authors:  Julian Freedland; Cinzia Cera; Michael Fasullo
Journal:  Mutat Res       Date:  2017-02-20       Impact factor: 2.433

9.  XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk.

Authors:  Xi Dai Long; Yun Ma; Yun Feng Zhou; Jin Guang Yao; Fu Zhi Ban; Yong Zhi Huang; Bing Cheng Huang
Journal:  BMC Cancer       Date:  2009-11-17       Impact factor: 4.430

10.  249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients.

Authors:  Jeronimo A Nogueira; Suzane K Ono-Nita; Marcelo E Nita; Marcelo M T de Souza; Eliane P do Carmo; Evandro S Mello; Cristovan Scapulatempo; Denise C Paranaguá-Vezozzo; Flair J Carrilho; Venancio A F Alves
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.